Cantargia (OMX: CANTA)

Last close As at 02/01/2026

SEK4.12

−0.07 (−1.55%)

Market capitalisation

SEK1,041m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Latest Insights

View More

Healthcare | Comment

Cantargia (OMX: CANTA) granted new US patent

Healthcare | Comment

Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka

Healthcare | Comment

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Goran Forsberg

    CEO